NovoSeven1 mg/vial

NovoSeven is a recombinant activated human coagulation factor VII used for hemostatic management under specialist supervision. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Treatment of bleeding episodes in patients with congenital hemophilia A or B with inhibitors to factor VIII or IX.
• Prevention of bleeding during surgical or other invasive procedures in patients with congenital hemophilia A or B with inhibitors.
• Treatment of bleeding episodes and perioperative (surgical) management in patients with acquired hemophilia (autoantibodies to factor VIII).
• Treatment of bleeding episodes and perioperative management in patients with congenital Factor VII deficiency.
• Treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia who are refractory to platelet transfusions, with or without antibodies to platelets.

Off-label / adjunct use (not routinely recommended)

• Uncontrolled or life-threatening hemorrhage in other settings (e.g. trauma, intracranial hemorrhage, cardiac surgery, liver disease) has been used off-label in some centers, but evidence is limited and use outside approved indications carries increased thrombotic risk; this use is not FDA-approved and should occur only under specialist direction in a hospital setting.

In all cases, NovoSeven should be initiated and dosed only by, or in close consultation with, a hematologist experienced in bleeding disorder management, ideally coordinated with a hemophilia treatment center.

Each single-use vial of Coagulation Factor VIIa [Eptacog Alfa] contains recombinant human coagulation factor VIIa as a lyophilized (freeze-dried) powder, available in strengths commonly including 1 mg, 2 mg, 5 mg and 8 mg per vial (potency also expressed in KIU). It is supplied with a diluent (e.g. histidine solution) for reconstitution before intravenous injection. Excipients typically include sodium chloride, calcium chloride dihydrate, glycylglycine, polysorbate 80, mannitol, sucrose and methionine; formulations do not contain any human-derived additives, though trace residual proteins from the manufacturing cell line (e.g. mouse, hamster, or bovine-derived materials) may be present depending on the specific product.

NovoSeven is a recombinant, activated form of human coagulation factor VII produced using genetic engineering (biotechnology). It works by promoting hemostasis (blood clot formation) at the site of vascular injury, largely independent of factors VIII and IX, which makes it valuable for patients whose bleeding cannot be controlled with standard factor replacement because they have developed inhibitors (neutralizing antibodies).

NovoSeven is administered only by intravenous injection in a hospital or specialist clinical setting, and is not intended for unsupervised home use without a structured, physician-directed treatment plan.

Boxed warning: Serious arterial and venous thromboembolic events, including fatal events, have been reported with NovoSeven, particularly when used outside approved indications and dosing, or in patients with underlying risk factors for thrombosis.

NovoSeven belongs to the therapeutic class of hemostatics (systemic antihemorrhagic agents), within the sub-class of recombinant coagulation factor concentrates used for management of bleeding disorders.

Mechanism of action

Coagulation Factor VIIa [Eptacog Alfa] is structurally similar to endogenous, plasma-derived activated factor VII. At the site of vascular injury, it binds to tissue factor exposed on subendothelial cells and, independently of factors VIII and IX, directly activates factor X on the surface of activated platelets. This generates a burst of thrombin sufficient to convert fibrinogen to fibrin, forming a stable hemostatic clot even in patients who lack, or have inhibitors against, factor VIII or IX.

Pharmacokinetics

Following intravenous administration, Coagulation Factor VIIa [Eptacog Alfa] reaches peak plasma concentration immediately, is distributed to a volume approximating the plasma volume, and is cleared with a terminal half-life of approximately 2.3 hours in adults (shorter in children, particularly younger children, who may require adjusted dosing intervals). Clearance occurs mainly via proteolytic degradation.

NovoSeven is given by slow intravenous (IV) bolus injection only, typically over 2-5 minutes, and must never be mixed with other infusion solutions or administered via the same IV line as other medicines without flushing. It must first be reconstituted with the diluent supplied with the product (see Reconstitution) and used promptly. Administration should take place in a facility equipped to manage bleeding emergencies and thrombotic complications, with patients monitored clinically for signs of inadequate hemostasis or thrombosis during and after treatment.

Formal drug-interaction studies with NovoSeven are limited; the following is a well-verified, clinically significant interaction:

• Activated prothrombin complex concentrates (aPCC) and other coagulation factor concentrates: Concurrent or closely-timed use with NovoSeven may increase the risk of thrombotic and thromboembolic complications through additive procoagulant effects. Concomitant use is generally not recommended unless specifically directed and closely monitored by a hematology specialist.
• Antifibrinolytic agents (e.g. tranexamic acid, aminocaproic acid): May be used adjunctively in some protocols, but combined use with NovoSeven should be guided by a specialist due to a theoretical additive thrombotic risk.

There is no clinically established interaction with common non-prescription medicines; however, patients should inform their physician of all medicines, supplements, and other coagulation products they are using before receiving NovoSeven.

Because NovoSeven is used in seriously ill patients with bleeding disorders, distinguishing drug-related effects from the underlying condition can be difficult. Reported adverse effects include:

Common

• Fever
• Injection/infusion site reactions
• Headache
• Hypertension or hypotension
• Nausea, vomiting
• Pain (including at the surgical or bleeding site)

Serious (uncommon but clinically important)

• Arterial and venous thromboembolic events (e.g. myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, intra-abdominal thrombosis) - see Precautions and Warnings for full detail.
• Hypersensitivity/allergic reactions, including rare anaphylaxis.
• Development of antibodies to factor VII (rare) or inhibitory antibodies in congenital Factor VII deficiency.

There are no well-controlled studies of NovoSeven in pregnant or breastfeeding women. Animal reproduction studies are limited. As with most biologic therapies used for serious bleeding, NovoSeven should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; treatment decisions should always be made in consultation with a physician, weighing the severity of the bleeding disorder against any theoretical risk.

It is not known whether NovoSeven is excreted in human milk. Caution is advised, and a physician should be consulted to weigh the benefits of breastfeeding against the mother's need for treatment.

Boxed warning: thrombosis

Serious arterial and venous thromboembolic events, including fatal events, have been reported with NovoSeven, particularly when used outside of approved indications and recommended dosing, or in patients with underlying risk factors for thrombosis such as advanced atherosclerotic disease, disseminated intravascular coagulation (DIC), severe liver disease, crush injury, sepsis, or concurrent use of activated prothrombin complex concentrates. Patients should be monitored for clinical signs and symptoms of thrombosis during and after treatment.

Specialist supervision required

NovoSeven requires dosing and monitoring individualized by a hematology specialist experienced in complex bleeding disorders. It is not intended for general outpatient use or self-titration without a specialist-directed protocol, and does not replace comprehensive hemophilia/bleeding disorder management, including monitoring of inhibitor titers and coordination with a hemophilia treatment center.

Lack of efficacy

If bleeding is not controlled after the recommended dose(s), the diagnosis and dosing regimen should be reassessed by the treating specialist before continuing therapy.

Antibody formation

Patients with congenital Factor VII deficiency or Glanzmann's thrombasthenia should be monitored for development of antibodies to Factor VII or platelets, respectively.

Doses of NovoSeven higher than recommended, or more frequent dosing than directed, increase the risk of thrombotic and thromboembolic complications. There is no specific antidote. If an overdose is suspected, or if symptoms suggestive of thrombosis occur (e.g. chest pain, shortness of breath, limb swelling, sudden weakness, or vision changes), the patient should seek immediate medical attention or contact emergency services; management is supportive and should occur under hospital/specialist care with monitoring for thrombosis.

Store NovoSeven according to the specific product's labeling. Unopened vials are generally stored refrigerated (2°C-8°C); some room-temperature-stable formulations may be kept below 30°C for a limited period within the labeled shelf life. Protect from light and do not freeze. After reconstitution, use promptly as directed by the product labeling (typically within a few hours) and discard any unused solution. Keep out of reach of children.

Pediatric patients

NovoSeven has been used in pediatric patients, including neonates, for congenital hemophilia with inhibitors, congenital Factor VII deficiency and Glanzmann's thrombasthenia, using the same weight-based dosing as adults; younger children may require shorter dosing intervals due to more rapid clearance. See Pediatric Uses for detail.

Elderly patients

Limited clinical data are available in patients over 65 years. Because thromboembolic risk is generally higher in older adults, particularly those with underlying atherosclerotic disease, NovoSeven should be used with added caution and close monitoring in this population.

Renal and hepatic impairment

No formal dose adjustment has been established for renal or hepatic impairment; however, severe liver disease is a recognized risk factor for thromboembolic complications with NovoSeven (see Precautions and Warnings), so such patients require closer monitoring.

Duration of treatment with NovoSeven is individualized by the treating hematology specialist based on the site and severity of bleeding, the indication being treated, and the clinical response. Dosing is typically continued at the intervals described in Dosage and Administration until hemostasis is confirmed, after which the dosing interval may be lengthened before stopping. For surgical or invasive-procedure prophylaxis, dosing is continued through the perioperative period as directed by the specialist protocol. Treatment should not be continued longer than necessary given the cumulative thrombotic risk with repeated dosing.

NovoSeven is supplied as a lyophilized powder that must be reconstituted before use. General steps (always follow the specific product's package insert):

1. Allow the vial of powder and the accompanying diluent to reach room temperature.
2. Using aseptic technique, reconstitute the powder with the volume of diluent specified for that vial strength, directing the diluent stream gently against the vial wall (do not shake vigorously).
3. Gently swirl until the powder is fully dissolved; the reconstituted solution should be clear or slightly opalescent and colorless.
4. Inspect visually for particulate matter or discoloration; do not use if present.
5. Use the reconstituted solution promptly (per product labeling, typically within a few hours when stored appropriately); do not mix with other infusion solutions.

Hemostatics; Systemic Antihemorrhagic Agents; Recombinant Coagulation Factor Concentrates

Coagulation Factor VIIa [Eptacog Alfa] promotes localized hemostasis by binding to tissue factor exposed at the site of vascular injury and, in a manner independent of coagulation factors VIII and IX, directly activating factor X on the surface of activated platelets. The resulting burst of thrombin converts fibrinogen to fibrin, producing a stable hemostatic plug even in patients who lack factor VIII/IX activity or have neutralizing inhibitors against them.

C (legacy FDA pregnancy category, assigned prior to the 2015 Pregnancy and Lactation Labeling Rule)

NovoSeven is used in pediatric patients, including neonates and infants, for the approved indications of congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, and Glanzmann's thrombasthenia, using the same weight-based (mcg/kg) dosing as adults. Because clearance of the drug is faster in younger children, shorter dosing intervals may be required to maintain hemostatic effect, as directed by a pediatric hematology specialist. Safety and efficacy for uses outside these established pediatric indications have not been established, and off-label pediatric use should occur only under specialist supervision in a hospital setting.